• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于世界卫生组织分类和 TERT 启动子突变的滤泡状甲状腺癌的超声特征与肿瘤侵袭性和预后的关系。

Association of Ultrasonography Features of Follicular Thyroid Carcinoma With Tumor Invasiveness and Prognosis Based on WHO Classification and TERT Promoter Mutation.

机构信息

Department of Radiology and Center for Imaging Science, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

出版信息

Korean J Radiol. 2024 Jan;25(1):103-112. doi: 10.3348/kjr.2023.0461.

DOI:10.3348/kjr.2023.0461
PMID:38184773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10788599/
Abstract

OBJECTIVE

To investigate the association of ultrasound (US) features of follicular thyroid carcinoma (FTC) with tumor invasiveness and prognosis based on the World Health Organization (WHO) classification and telomerase reverse transcriptase (TERT) promoter mutations.

MATERIALS AND METHODS

This retrospective study included 54 surgically confirmed FTC patients with US images and TERT promoter mutations (41 females and 13 males; median age [interquartile range], 40 years [30-51 years]). The WHO classification consisted of minimally invasive (MI), encapsulated angioinvasive (EA), and widely invasive (WI) FTCs. Alternative classifications included Group 1 (MI-FTC and EA-FTC with wild type TERT), Group 2 (WI-FTC with wild type TERT), and Group 3 (EA-FTC and WI-FTC with mutant TERT). Each nodule was categorized according to the US patterns of the Korean Thyroid Imaging Reporting and Data System (K-TIRADS) and American College of Radiology-TIRADS (ACR-TIRADS). The Jonckheere-Terpstra and Cochran-Armitage tests were used for statistical analysis.

RESULTS

Among 54 patients, 29 (53.7%) had MI-FTC, 16 (29.6%) had EA-FTC, and nine (16.7%) had WI-FTC. In both the classifications, lobulation, irregular margins, and final assessment categories showed significant differences (all ≤ 0.04). Furthermore, the incidences of lobulation, irregular margin, and high suspicion category tended to increase with increasing tumor invasiveness and worse prognosis (all for trend ≤ 0.006). In the WHO groups, hypoechogenicity differed significantly among the groups ( = 0.01) and tended to increase in proportion as tumor invasiveness increased ( for trend = 0.02). In the alternative group, punctate echogenic foci were associated with prognosis ( = 0.03, for trend = 0.03).

CONCLUSION

Increasing tumor invasiveness and worsening prognosis in FTC based on the WHO classification and TERT promoter mutation results were positively correlated with US features that indicate malignant probability according to both K-TIRADS and ACR-TIRADS.

摘要

目的

基于世界卫生组织(WHO)分类和端粒酶逆转录酶(TERT)启动子突变,研究滤泡状甲状腺癌(FTC)的超声(US)特征与肿瘤侵袭性和预后的关系。

材料与方法

本回顾性研究纳入 54 例经手术证实的 FTC 患者,均有 US 图像和 TERT 启动子突变(41 名女性,13 名男性;中位年龄[四分位数范围],40 岁[30-51 岁])。WHO 分类包括微侵袭性(MI)、包裹性血管侵袭性(EA)和广泛侵袭性(WI)FTC。替代分类包括 1 组(MI-FTC 和 EA-FTC 伴野生型 TERT)、2 组(WI-FTC 伴野生型 TERT)和 3 组(EA-FTC 和 WI-FTC 伴突变型 TERT)。根据韩国甲状腺影像报告和数据系统(K-TIRADS)和美国放射学院-TIRADS(ACR-TIRADS)的 US 模式对每个结节进行分类。Jonckheere-Terpstra 和 Cochran-Armitage 检验用于统计分析。

结果

在 54 例患者中,29 例(53.7%)为 MI-FTC,16 例(29.6%)为 EA-FTC,9 例(16.7%)为 WI-FTC。在两种分类中,分叶、不规则边缘和最终评估类别均有显著差异(均 ≤0.04)。此外,随着肿瘤侵袭性的增加和预后的恶化,分叶、不规则边缘和高度可疑类别出现的比例呈增加趋势(所有趋势 ≤0.006)。在 WHO 组中,各组之间的低回声差异有统计学意义( =0.01),随着肿瘤侵袭性的增加,这种差异呈增加趋势(趋势 =0.02)。在替代组中,点状强回声灶与预后相关( =0.03,趋势 =0.03)。

结论

根据 WHO 分类和 TERT 启动子突变结果,FTC 的肿瘤侵袭性增加和预后恶化与 K-TIRADS 和 ACR-TIRADS 均提示恶性概率的 US 特征呈正相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9969/10788599/d73026e50725/kjr-25-103-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9969/10788599/a2287cafa9f1/kjr-25-103-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9969/10788599/c843da11a86a/kjr-25-103-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9969/10788599/fb54d775cae5/kjr-25-103-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9969/10788599/d73026e50725/kjr-25-103-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9969/10788599/a2287cafa9f1/kjr-25-103-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9969/10788599/c843da11a86a/kjr-25-103-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9969/10788599/fb54d775cae5/kjr-25-103-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9969/10788599/d73026e50725/kjr-25-103-g004.jpg

相似文献

1
Association of Ultrasonography Features of Follicular Thyroid Carcinoma With Tumor Invasiveness and Prognosis Based on WHO Classification and TERT Promoter Mutation.基于世界卫生组织分类和 TERT 启动子突变的滤泡状甲状腺癌的超声特征与肿瘤侵袭性和预后的关系。
Korean J Radiol. 2024 Jan;25(1):103-112. doi: 10.3348/kjr.2023.0461.
2
Role of ultrasound in predicting telomerase reverse transcriptase (TERT) promoter mutation in follicular thyroid carcinoma.超声在预测滤泡状甲状腺癌中端粒酶逆转录酶(TERT)启动子突变中的作用。
Sci Rep. 2024 Jul 3;14(1):15323. doi: 10.1038/s41598-024-66351-z.
3
Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations.基于 TERT 启动子突变的滤泡状甲状腺癌的分子分类。
Mod Pathol. 2022 Feb;35(2):186-192. doi: 10.1038/s41379-021-00907-6. Epub 2021 Sep 8.
4
Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status.滤泡性甲状腺癌原发肿瘤大小和 TERT 启动子突变状态用于甲状腺全切术选择的标准。
Ann Surg Oncol. 2023 May;30(5):2916-2925. doi: 10.1245/s10434-022-13089-5. Epub 2023 Jan 13.
5
Comparison of the diagnostic performance of three ultrasound thyroid nodule risk stratification systems for follicular thyroid neoplasm: K-TIRADS, ACR -TIRADS and C-TIRADS.三种超声甲状腺结节危险分层系统(K-TIRADS、ACR-TIRADS 和 C-TIRADS)对滤泡性甲状腺肿瘤的诊断性能比较。
Clin Hemorheol Microcirc. 2023;85(4):395-406. doi: 10.3233/CH-231898.
6
Role of Ultrasound in Predicting Tumor Invasiveness in Follicular Variant of Papillary Thyroid Carcinoma.超声在预测甲状腺滤泡型乳头状癌肿瘤侵袭性中的作用。
Thyroid. 2017 Sep;27(9):1177-1184. doi: 10.1089/thy.2016.0677. Epub 2017 Aug 7.
7
Can ultrasound systems for risk stratification of thyroid nodules identify follicular carcinoma?超声系统能否对甲状腺结节进行危险分层以识别滤泡癌?
Cancer Cytopathol. 2020 Apr;128(4):250-259. doi: 10.1002/cncy.22235. Epub 2020 Jan 3.
8
Mutation profiles of follicular thyroid tumors by targeted sequencing.通过靶向测序分析滤泡性甲状腺肿瘤的突变谱。
Diagn Pathol. 2019 May 10;14(1):39. doi: 10.1186/s13000-019-0817-1.
9
Preoperative sonographic features of follicular thyroid carcinoma predict biological behavior: A retrospective study.滤泡状甲状腺癌的术前超声特征可预测生物学行为:一项回顾性研究。
Medicine (Baltimore). 2018 Oct;97(41):e12814. doi: 10.1097/MD.0000000000012814.
10
TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.TERT 启动子突变在转移性滤泡状甲状腺癌中的空间异质性:对临床检查的影响。
Endocr Pathol. 2019 Sep;30(3):246-248. doi: 10.1007/s12022-019-09580-7.

引用本文的文献

1
Prospective Validation of an Ultrasound Capsule-Based Model for Predicting Follicular Thyroid Carcinoma Without High-Risk Features.基于超声胶囊模型预测无高风险特征的滤泡性甲状腺癌的前瞻性验证
Cancer Med. 2025 Sep;14(17):e71190. doi: 10.1002/cam4.71190.
2
Prognostic significance of clinicopathological and ultrasonographic features in anaplastic thyroid carcinoma beyond TERT promoter mutation.TERT启动子突变以外的间变性甲状腺癌的临床病理及超声特征的预后意义
Sci Rep. 2025 Apr 5;15(1):11736. doi: 10.1038/s41598-025-96774-1.
3
Role of ultrasound in predicting telomerase reverse transcriptase (TERT) promoter mutation in follicular thyroid carcinoma.

本文引用的文献

1
Thyroid Nodule Margin Assessment Using ACR TI-RADS: Adding Points for Macrolobulation Impairs Performance.使用美国放射学会甲状腺影像报告和数据系统(ACR TI-RADS)评估甲状腺结节边缘:为分叶状增加评分会降低诊断效能。
J Ultrasound Med. 2023 Feb;42(2):409-415. doi: 10.1002/jum.16034. Epub 2022 Jun 7.
2
2021 Korean Thyroid Imaging Reporting and Data System and Imaging-Based Management of Thyroid Nodules: Korean Society of Thyroid Radiology Consensus Statement and Recommendations.2021 年韩国甲状腺影像报告和数据系统及基于影像学的甲状腺结节管理:韩国甲状腺放射学会共识声明和建议。
Korean J Radiol. 2021 Dec;22(12):2094-2123. doi: 10.3348/kjr.2021.0713. Epub 2021 Oct 26.
3
超声在预测滤泡状甲状腺癌中端粒酶逆转录酶(TERT)启动子突变中的作用。
Sci Rep. 2024 Jul 3;14(1):15323. doi: 10.1038/s41598-024-66351-z.
Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations.
基于 TERT 启动子突变的滤泡状甲状腺癌的分子分类。
Mod Pathol. 2022 Feb;35(2):186-192. doi: 10.1038/s41379-021-00907-6. Epub 2021 Sep 8.
4
The Value of Sonography in Distinguishing Follicular Thyroid Carcinoma from Adenoma.超声检查在鉴别甲状腺滤泡癌与腺瘤中的价值。
Cancer Manag Res. 2021 May 17;13:3991-4002. doi: 10.2147/CMAR.S307166. eCollection 2021.
5
Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South Korea: A Multicenter Cohort Study.世界卫生组织分类在韩国滤泡性甲状腺癌患者中的临床意义:一项多中心队列研究。
Endocrinol Metab (Seoul). 2020 Sep;35(3):618-627. doi: 10.3803/EnM.2020.742. Epub 2020 Sep 22.
6
Conventional ultrasound characteristics, TI-RADS category and shear wave speed measurement between follicular adenoma and follicular thyroid carcinoma.滤泡性腺瘤与甲状腺滤泡癌之间的传统超声特征、TI-RADS分类及剪切波速度测量
Clin Hemorheol Microcirc. 2020;75(3):291-301. doi: 10.3233/CH-190750.
7
Suspicious ultrasound and clinicopathological features of papillary thyroid carcinoma predict the status of TERT promoter.甲状腺乳头状癌可疑的超声及临床病理特征可预测端粒酶逆转录酶(TERT)启动子状态。
Endocrine. 2020 May;68(2):349-357. doi: 10.1007/s12020-020-02214-7. Epub 2020 Feb 5.
8
Ultrasound-guided fine-needle aspiration or core needle biopsy for diagnosing follicular thyroid carcinoma?超声引导下细针抽吸活检或核心针活检用于诊断滤泡甲状腺癌?
Clin Endocrinol (Oxf). 2020 May;92(5):468-474. doi: 10.1111/cen.14167. Epub 2020 Feb 25.
9
Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.TERT 启动子突变与分化型甲状腺癌临床行为的关系:系统评价和荟萃分析。
Endocrine. 2020 Jan;67(1):44-57. doi: 10.1007/s12020-019-02117-2. Epub 2019 Oct 26.
10
The 2017 Bethesda System for Reporting Thyroid Cytopathology.2017年甲状腺细胞病理学报告贝塞斯达系统
J Am Soc Cytopathol. 2017 Nov-Dec;6(6):217-222. doi: 10.1016/j.jasc.2017.09.002. Epub 2017 Sep 14.